Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01071850 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 412
- Enrollment target
- 20
- Study locations
NCT01071850 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Astellas Pharma. The registered enrollment target is 412 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT01071850, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 412 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG ipragliflozin
Study Locations (20)
California
- Clinical Innovations, Inc. - Costa Mesa
- Del Rosario Medical Clinic, Inc - Huntington Park
- Torrance Clinical Research - Lomita
- San Diego Managed Care Group Clinical Research - San Diego
Florida
- PAB Clinical Research - Brandon
- Clinical Therapeutics Corp. - Coral Gables
- A.G.A Clinical Trials DBA Neostart Group - Hialeah
- Suncoast Clinical Research - New Port Richey
Alabama
- Parkway Medical Center - Birmingham
- Winston Technology Research, LLC - Haleyville
Arizona
- Desert Clinical Research - Mesa
- Central Phoenix Medical Clinic - Phoenix
Georgia
- CSRA Partners in Health, Inc. - Augusta
- Atlanta Vascular Research Foundation, Atlanta Cardiology & Primary Care P.C. - Tucker
Illinois
- Cedar Crosse Research Center - Chicago
- APEX Medical Research, AMR, Inc - Chicago
Arkansas
- Paul W. Davis, MD, PA - Pine Bluff
Colorado
- Expresscare Clinical Research - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2010-03-03 |
| Est. Completion | 2011-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01071850
The ClinicalTrials.gov registry entry for NCT01071850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (91% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01071850 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01071850 about?
NCT01071850 is a clinical study titled "A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus". Evaluate the efficacy, safety, and tolerability of multiple doses of ASP1941 compared to placebo over 12 weeks of therapy in adult patients with type 2 diabetes mellitus.
What is the current status of trial NCT01071850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 412 participants. The study started on 2010-03-03. Estimated completion is 2011-04-11.
What conditions does trial NCT01071850 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01071850?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), ipragliflozin (DRUG).
Who is sponsoring clinical trial NCT01071850?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01071850 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.